Gamaleya Research Institute of Epidemiology and Microbiology
OrganizationMentioned in 1 video
A Russian institute that developed a two-dose adenovirus-vectored COVID-19 vaccine, publicly distributed before complete phase 3 trial data was available.
A Russian institute that developed a two-dose adenovirus-vectored COVID-19 vaccine, publicly distributed before complete phase 3 trial data was available.